Short Interest Coverage: Antares Pharma Incorporated (NASDAQ:ATRS) Shorted Shares Increased 3.45% After Market Selling

November 25, 2016 - By Linda Rogers   ·   0 Comments

Short Interest Coverage: Antares Pharma Incorporated (NASDAQ:ATRS) Shorted Shares Increased 3.45% After Market Selling

The stock of Antares Pharma Incorporated (NASDAQ:ATRS) registered an increase of 3.45% in short interest. ATRS’s total short interest was 2.92 million shares in November as published by FINRA. Its up 3.45% from 2.82M shares, reported previously. With 417,700 shares average volume, it will take short sellers 7 days to cover their ATRS’s short positions. The short interest to Antares Pharma Incorporated’s float is 2.58%. The stock increased 4.26% or $0.08 on November 23, hitting $1.96. Antares Pharma Inc (NASDAQ:ATRS) has risen 92.16% since April 22, 2016 and is uptrending. It has outperformed by 86.75% the S&P500.

Antares Pharma, Inc. is a specialty pharmaceutical firm that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The company has a market cap of $316.90 million. The Firm develops and makes pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. It currently has negative earnings. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors.

Insitutional Activity: The institutional sentiment increased to 0.82 in 2016 Q2. Its up 0.19, from 0.63 in 2016Q1. The ratio increased, as 28 funds sold all Antares Pharma Inc shares owned while 21 reduced positions. 16 funds bought stakes while 15 increased positions. They now own 55.56 million shares or 16.31% less from 66.39 million shares in 2016Q1.
Blackrock Institutional Com Na holds 0% or 2.82M shares in its portfolio. Lmr Ltd Liability Partnership last reported 282,738 shares in the company. D E Shaw & last reported 0% of its portfolio in the stock. Royal Bank & Trust Of Canada holds 0% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS) for 10,350 shares. Kingdon Cap Management has 0.07% invested in the company for 1.28 million shares. Citigroup accumulated 8,362 shares or 0% of the stock. Jw Asset Mgmt Ltd Llc owns 475,897 shares or 0.4% of their US portfolio. Creative Planning last reported 0% of its portfolio in the stock. Pnc Service Gp Inc, a Pennsylvania-based fund reported 675 shares. Two Sigma Securities Ltd Co accumulated 20,609 shares or 0.01% of the stock. Bnp Paribas Arbitrage Sa last reported 29 shares in the company. Schwab Charles Mngmt has 0% invested in the company for 217,598 shares. Moreover, Avenir has 0.03% invested in Antares Pharma Inc (NASDAQ:ATRS) for 321,535 shares. Goldman Sachs, a New York-based fund reported 297,915 shares. Broadfin Cap Ltd Llc last reported 1.52% of its portfolio in the stock.

ATRS Company Profile

Antares Pharma, Inc. (Antares), incorporated on April 29, 2005, is a specialty pharmaceutical firm that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Firm develops and makes pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Firm makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Firm operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.

More recent Antares Pharma Inc (NASDAQ:ATRS) news were published by: Globenewswire.com which released: “Antares Pharma to Present at the 28th Annual Piper Jaffray Healthcare Conference” on November 23, 2016. Also Seekingalpha.com published the news titled: “Antares Pharmaceuticals: The Stock To Buy On EpiPen Issues” on August 28, 2016. Globenewswire.com‘s news article titled: “Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief …” with publication date: October 31, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>